Metformin

• 

  Subject Areas on Research

  • A quantitative measure of diabetes risk in community practice impacts clinical decisions: the PREVAIL initiative. 
  • A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. 
  • Altering hirsutism through ovulation induction in women with polycystic ovary syndrome. 
  • Antidiabetic therapies affect risk of pancreatic cancer. 
  • Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes. 
  • CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. 
  • Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. 
  • Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas. 
  • Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. 
  • Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. 
  • Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. 
  • Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. 
  • Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. 
  • Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells. 
  • Early atherosclerosis is associated with retinal microvascular changes in adolescents with type 1 diabetes. 
  • Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. 
  • Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. 
  • Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. 
  • Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome. 
  • Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial. 
  • Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. 
  • Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. 
  • Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin. 
  • Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. 
  • HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. 
  • Intercourse compliance, ovulation, and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial. 
  • Lactic acidosis in patients with diabetes treated with metformin. 
  • Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. 
  • Long-term metformin usage and cognitive function among older adults with diabetes. 
  • Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. 
  • Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial. 
  • Metabolic syndrome: evaluation of pathological and therapeutic outcomes. 
  • Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. 
  • Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. 
  • Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes. 
  • Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. 
  • Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. 
  • Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. 
  • Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. 
  • Metformin is associated with improved survival in endometrial cancer. 
  • Metformin mitigates apoptosis in ischemic myocardium. 
  • Metformin reverses fatty liver disease in obese, leptin-deficient mice. 
  • Metformin use and risk of prostate cancer: results from the REDUCE study. 
  • Metformin use is associated with better survival of diabetic patients with pancreatic cancer. 
  • Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer-Response. 
  • Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer. 
  • Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. 
  • New combination treatments in the management of diabetes: focus on sitagliptin-metformin. 
  • New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. 
  • One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. 
  • Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. 
  • Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. 
  • Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. 
  • Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. 
  • Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial. 
  • Screening for Obesity in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. 
  • Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. 
  • Sex-specific differences in diabetes prevention: a systematic review and meta-analysis. 
  • Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. 
  • Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. 
  • The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. 
  • The clinical treatment of childhood obesity. 
  • The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. 
  • The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 
  • The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. 
  • The use of insulin secretagogues in the treatment of type 2 diabetes. 
  • Treatment of diabetes mellitus: implications of the use of oral agents. 
  • Treatment of diabetes mellitus: implications of the use of oral agents. 
  • Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.